Recombinant human IgG antibodies recognizing distinct extracellular domains of EGF receptor exhibit different degrees of growth inhibitory effects on human A431 cancer cells

Experimental Cell Research

Volumn 319, Issue 8, 2013, Pages 1146-1155

  Chang, Chialun ^a,b   Takayanagi, Atsushi ^a,b   Yoshida, Tetsuhiko ^c   Shimizu, Nobuyoshi ^a  

^a KEIO UNIVERSITY   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Base Technology Center   (Japan)

Author keywords

Antibody; Apoptosis; EGF receptor; Epitope; Phage display; Phosphorylation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPITOPE; IMMUNOGLOBULIN G; RECOMBINANT ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; CANCER CELL; CANCER INHIBITION; CHO CELL; CONTROLLED STUDY; DELETION MUTANT; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOPRECIPITATION; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 84876086025     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2013.03.002     Document Type: Article

References (38)

1. Fukuyama R., Shimizu N. Expression of epidermal growth factor (EGF) and the EGF receptor in human tissues. J. Exp. Zool. 1991, 258:336-343.
2. Ozawa S., Ueda M., Ando N., Shimizu N., Abe O. Prognostic significance of epidermal growth factor receptor in esophageal squamous cell carcinomas. Cancer 1989, 63:2169-2173.
3. Gamou S., Shimagaki M., Minoshima S., Kobayashi S., Shimizu N. Subcellular localization of the EGF receptor maturation process. Exp. Cell Res. 1989, 183:197-206.
4. Zhang X., Gureasko J., Shen K., Cole P.A., Kuriyan J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 2006, 125:1137-1149.
5. Jura N., Endres N.F., Engel K., Deindl S., Das R., Lamers M.H., Wemmer D.E., Zhang X., Kuriyan J. Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Cell 2009, 137:1293-1307.
6. Garrett T.P., McKern N.M., Lou M., Elleman T.C., Adams T.E., Lovrecz G.O., Zhu H.J., Walker F., Frenkel M.J., Hoyne P.A., Jorissen R.N., Nice E.C., Burgess A.W., Ward C.W. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 2002, 110:763-773.
7. Ogiso H., Ishitani R., Nureki O., Fukai S., Yamanaka M., Kim J.-H., Saito K., Sakamoto A., Inoue M., Shirouzu M., Yokoyama S. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 2002, 110:775-787.
8. Imai K., Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat. Rev. Cancer 2006, 6:714-727.
9. Takeuchi K., Ito F. EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors. FEBS J. 2010, 277:316-326.
10. Jakobovits A., Amado R.G., Yang X., Roskos L., Schwab G. From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat. Biotechnol. 2007, 25:1134-1143.
11. Berger C., Krengel U., Stang E., Moreno E., Madshus I.Helene Nimotuzumab and cetuximab block ligand-independent EGF receptor signaling efficiently at different concentrations. J. Immunother 2011, 34:550-555.
12. Schmitz K.R., Ferguson K.M. Interaction of antibodies with ErbB receptor extracellular regions. Exp. Cell Res. 2009, 315:659-670.
13. Shimizu N., Behzadian M.A., Shimizu Y. Genetics of cell surface receptors for bioactive polypeptides: binding of epidermal growth factor is associated with the presence of human chromosome 7 in human-mouse cell hybrids. Proc. Nat. Acad. Sci. U.S.A. 1980, 77:3600-3604.
14. Chang C., Takayanagi A., Yoshida T., Shimizu N. Screening of scFv-displaying phages recognizing distinct extracellular domains of EGF receptor by target-guided proximity labeling method. J. Immunol. Methods 2011, 372:127-136.
15. Behzadian M.A., Shimizu N. Monoclonal antibody that immunoreacts with a subclass of human receptors for epidermal growth factor. Cell Struct. Funct. 1985, 10:219-232.
16. Hudson P.J., Kortt A.A. High avidity scFv multimers; diabodies and triabodies. J. Immunol. Methods 1999, 231:177-189.
17. Yokota T., Milenic D.E., Whitlow M., Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 1992, 52:3402-3408.
18. Huston J.S., McCartney J., Tai M.S., Mottola-Hartshorn C., Jin D., Warren F., Keck P., Oppermann H. Medical applications of single-chain antibodies. Int. Rev. Immunol. 1993, 10:195-217.
19. Colcher D., Goel A., Pavlinkova G., Beresford G., Booth B., Batra S.K. Effects of genetic engineering on the pharmacokinetics of antibodies. Q. J. Nucl. Med. 1999, 43:132-139.
20. Kubota T., Niwa R., Satoh M., Akinaga S., Shitara K., Hanai N. Engineered therapeutic antibodies with improved effector functions. Cancer Sci. 2009, 100:1566-1572.
21. Weiner L.M., Surana R., Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 2010, 10:317-327.
22. Houot R., Kohrt H.E., Marabelle A., Levy R. Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy. Trends Immunol. 2011, 32:510-516.
23. Gamou S., Shimizu N. Hydrogen peroxide preferentially enhances the tyrosine phosphorylation of epidermal growth factor receptor. FEBS Lett. 1995, 357:161-164.
24. Zhen Y., Caprioli R.M., Staros J.V. Characterization of glycosylation sites of the epidermal growth factor receptor. Biochemistry 2003, 42:5478-5492.
25. Rieber M., Rieber M.S. Cyclin D1 overexpression induces epidermal growth factor-independent resistance to apoptosis linked to BCL-2 in human A431 carcinoma. Apoptosis 2006, 11:121-129.
26. Jura N., Zhang X., Endres N.F., Seeliger M.A., Schindler T., Kuriyan J. Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms. Mol. Cell 2011, 42:9-22.
27. Jorissen R.N., Walker F., Pouliot N., Garrett T.P.J., Ward C.W., Burgess A.W. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp. Cell Res. 2003, 284:31-53.
28. Lau S.K., Shields D.J., Murphy E.A., Desgrosellier J.S., Anand S., Huang M., Kato S., Lim S.T., Weis S.M., Stupack D.G., Schlaepfer D.D., Cheresh D.A. EGFR-mediated carcinoma cell metastasis mediated by integrin alphavbeta5 depends on activation of c-Src and cleavage of MUC1. PLoS One 2012, 7:e36753.
29. Simbulan-Rosenthal C.M., Rosenthal D.S., Iyer S., Boulares H., Smulson M.E. Involvement of PARP and poly(ADP-ribosyl)ation in the early stages of apoptosis and DNA replication. Mol. Cell. Biochem. 1999, 193:137-148.
30. You B., Chen E.X. Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of cetuximab and Panitumumab. J. Clin. Pharm. 2011.
31. Yang X.D., Jia X.C., Corvalan J.R., Wang P., Davis C.G., Jakobovits A. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. 1999, 59:1236-1243.
32. Baselga J. The EGFR as a target for anticancer therapy-focus on cetuximab. Eur. J. Cancer 2001, 37(Suppl 4):S16-22.
33. Li S., Schmitz K.R., Jeffrey P.D., Wiltzius J.J., Kussie P., Ferguson K.M. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005, 7:301-311.
34. Foon K.A., Yang X.D., Weiner L.M., Belldegrun A.S., Figlin R.A., Crawford J., Rowinsky E.K., Dutcher J.P., Vogelzang N.J., Gollub J., Thompson J.A., Schwartz G., Bukowski R.M., Roskos L.K., Schwab G.M. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int. J. Radiat. Oncol. Biol. Phys. 2004, 58:984-990.
35. Li S., Kussie P., Ferguson K.M. Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8. Structure 2008, 16:216-227.
36. Harari P.M. Epidermal growth factor receptor inhibition strategies in oncology. Endocr. Relat. Cancer 2004, 11:689-708.
37. Cho H.S., Mason K., Ramyar K.X., Stanley A.M., Gabelli S.B., Denney D.W., Leahy D.J. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003, 421:756-760.
38. Crombet T., Osorio M., Cruz T., Roca C., del Castillo R., Mon R., Iznaga-Escobar N., Figueredo R., Koropatnick J., Renginfo E., Fernandez E., Alvarez D., Torres O., Ramos M., Leonard I., Perez R., Lage A. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J. Clin. Oncol. 2004, 22:1646-1654.